Do you want to read an article? Please log in or register.
Optimizing Duration and Dosing Frequency of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori: A Multicenter Randomized Trial
Helicobacter Pylori
Related content
Helicobacter Pylori
Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial
Helicobacter
Cheung KS, Lyu T, Deng Z, Han S, Ni L, Wu J, Tan JT, Qin J, Ng HY, Leung WK, Seto WK
doi: 10.1111/hel.13133
Helicobacter Pylori
Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial
Helicobacter
Yan TL, Wang JH, Zhu RK, Zhai HL, Wang ZZ, Mao XL, Shen X, Xu P, Ma D, He XJ, Wang JW, Gao JG, Jiang LL, Sun K, Chen Y, Sang JZ, Liu XQ, Chen JE, Li L
doi: 10.1111/hel.70056
Helicobacter Pylori
Comparison of Therapeutic Outcomes Between Concomitant Therapy and Tailored Therapy for Helicobacter pylori: A Multicenter, Prospective, and Randomized Study
Helicobacter
Cho YS, Kim SM, Kang SH, Moon HS, Sung JK, Bang KB, Ryou SH, Kim KB, Sul HJ, Lee SW
doi: 10.1111/hel.70040
Helicobacter Pylori
Optimal Duration of Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis
Helicobacter
Duan M, Kong Q, Wang H, Li Y
doi: 10.1111/hel.13144
Gastrointestinal CancerHelicobacter Pylori
Eradication Therapy to Prevent Gastric Cancer in H. pylori-positive individuals: Systematic Review and Meta-analysis of Randomized Controlled Trials and Observational Studies
Gastroenterology
Ford AC, Yuan Y, Park JY, Forman D, Moayyedi P
doi: 10.1053/j.gastro.2024.12.033
RECOMMENDED
Helicobacter Pylori
PROBIOTICS PRESCRIBED WITH HELICOBACTER PYLORI ERADICATION THERAPY IN EUROPE: USAGE PATTERN, EFFECTIVENESS, AND SAFETY: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg)
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Am J Gastroenterol
Deza DC, Alcedo J, Lafuente M, López FJ, Perez-Aisa Á, Pavoni M, Tepes B, Jonaitis L, Castro-Fernandez M, Pabón-Carrasco M, Keco-Huerga A, Voynovan I, Bujanda L, Lucendo AJ, Jurecic NB, Denkovski M, Vologzanina L, Rodrigo L, Martínez-Domínguez SJ, Fadieienko G, Huguet JM, Abdulkhakov R, Abdulkhakov SR, Alcaide N, Velayos B, Hernández L, Bordin DS, Gasbarrini A, Kupcinskas J, Babayeva G, Gridnyev O, Leja M, Rokkas T, Marcos-Pinto R, Lerang F, Boltin D, Mestrovic A, Smith SM, Venerito M, Boyanova L, Milivojevic V, Doulberis M, Kunovsky L, Parra P, Cano-Català A, Moreira L, Nyssen OP, Megraud F, Morain CO, Gisbert JP, Hp-EuReg investigators
doi: 10.14309/ajg.0000000000003351
Inflammatory Bowel Disease
Group-Delivered Mindfulness-Based Cognitive Therapy to Reduce Psychological Distress and Improve Sleep in Patients With Inflammatory Bowel Diseases: A Multicenter Randomized Controlled Trial (MindIBD)
Inflamm Bowel Dis
Ter Avest MM, Huijbers MJ, Horjus CS, Römkens TEH, Witteman EM, van Dop WA, Dresler M, Donders ART, Dijkstra G, Nissen LHC, Speckens AEM
doi: 10.1093/ibd/izaf116
Helicobacter Pylori
Efficacy of Tegoprazan-Containing Sequential Eradication Treatment Compared to Esomeprazole-Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study
Helicobacter
Lee JW, Kim N, Lee J, Jo SY, Lee DH
doi: 10.1111/hel.13143
RECOMMENDED
Helicobacter Pylori
The Optimal Age of Helicobacter pylori Screen-and-Treat for Gastric Cancer Prevention in the United States
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Helicobacter
Mülder DT, O'Mahony JF, Sun D, van Duuren LA, van den Puttelaar R, Harlass M, Han W, Huang RJ, Spaander MCW, Ladabaum U, Lansdorp-Vogelaar I
doi: 10.1111/hel.70039